Life sciences industry’s response to COVID-19 disruptions has evolved over the course of the year. The SARS-CoV-2 virus, first emerged as an unknown pneumonia-like disease in December 2019, and ultimately gained the status of a global health crisis, by March 2020. Enforced lockdowns and safety measures caused temporary shutdown of labs and production facilities, and further interference, longterm.
Next, in response to COVID-19, the industry’s attention was shifted towards developing a pandemic cure, which in turn dampened the demand for non-COVID-19 products and clinical trials. Ultimately, companies and government organizations were compelled to find ways to respond to emerging challenges and adapt to the new normal.
To gain insight from the response of life sciences industry to COVID-19, and the current market scenarios, through the major developments in the industry over the past six months, download this infographic.